Results 101 to 110 of about 1,677,629 (133)
Some of the next articles are maybe not open access.
Long-Term Safety of Once-Nightly Sodium Oxybate: Interim Analysis of Data From RESTORE (P5-13.005)
Neurology, 2023John Harsh +2 more
exaly +2 more sources
0638 Stability of Once-Nightly Sodium Oxybate in Alternative Liquid Reconstitution Vehicles
SLEEPAbstract Introduction LUMRYZ™ is a once-nightly formulation of sodium oxybate (ON-SXB) containing both immediate and pH-dependent controlled-release granules designed to be reconstituted in water and administered orally.
Maggie Lavender +6 more
openaire +1 more source
SLEEP
Abstract Introduction Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing ...
Maggie Lavender +5 more
openaire +1 more source
Abstract Introduction Sodium oxybate, available in once-nightly and twice-nightly formulations, is indicated for treatment of cataplexy or excessive daytime sleepiness in narcolepsy. Once-nightly sodium oxybate extended-release oral suspension (ON-SXB; LUMRYZ™) may alleviate potential dosing ...
Maggie Lavender +5 more
openaire +1 more source
SLEEP
Abstract Introduction The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
Heidy Merius +5 more
openaire +1 more source
Abstract Introduction The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
Heidy Merius +5 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) demonstrated efficacy in treating narcolepsy symptoms, including disrupted nighttime sleep (DNS), in the phase 3 REST-ON trial (NCT02720744). This post hoc analysis assessed ON-SXB efficacy on DNS across various participant subgroups.
Yves Dauvilliers +7 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) demonstrated efficacy in treating narcolepsy symptoms, including disrupted nighttime sleep (DNS), in the phase 3 REST-ON trial (NCT02720744). This post hoc analysis assessed ON-SXB efficacy on DNS across various participant subgroups.
Yves Dauvilliers +7 more
openaire +1 more source
SLEEP
Abstract Introduction Extended-release, once-nightly sodium oxybate (ON-SXB; LUMRYZ™) eliminates the middle-of-the-night dosing required with immediate-release, twice-nightly oxybates (TN-OXBs). RESTORE (NCT04451668) was an open label/switch study that assessed the safety and tolerability of ON-SXB in
Adrian Santamaria +7 more
openaire +1 more source
Abstract Introduction Extended-release, once-nightly sodium oxybate (ON-SXB; LUMRYZ™) eliminates the middle-of-the-night dosing required with immediate-release, twice-nightly oxybates (TN-OXBs). RESTORE (NCT04451668) was an open label/switch study that assessed the safety and tolerability of ON-SXB in
Adrian Santamaria +7 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness and cataplexy in adult and pediatric patients ≥7 years of age with narcolepsy. The REFRESH study assesses the clinical effectiveness, patient satisfaction, and safety of ON-SXB for the
Sarah Meskill +9 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness and cataplexy in adult and pediatric patients ≥7 years of age with narcolepsy. The REFRESH study assesses the clinical effectiveness, patient satisfaction, and safety of ON-SXB for the
Sarah Meskill +9 more
openaire +1 more source
DOSE TITRATION AND TOLERABILITY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM DATA FROM RESTORE
Chest, 2022ASIM ROY +5 more
openaire +1 more source
Long-Term Safety of Once-Nightly Sodium Oxybate: Interim Data From RESTORE
Sleep Medicine, 2022T. Stern +8 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy +7 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) or 2 (NT2) in the phase 3 REST-ON trial; treatment with 6, 7.5, and 9 g demonstrated significant improvements vs placebo (all P< 0.001) for the coprimary endpoints of ...
Michael Thorpy +7 more
openaire +1 more source